Key facts
- It has raised $3.4M across 2 recorded rounds; the latest was Seed Round ($2.3M) in May 2025.
- ROSE Diagnostics has filed 2 Form Ds with the SEC since 2024, most recently May 2025 ($2.3M sold to 18 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for ROSE Diagnostics
Funding rounds
2 roundsAbout ROSE Diagnostics
Developer of lymph biomarkers designed for cancer diagnostics. The company's product uses a multiplexed dynamic predictive algorithm, sandwiched immunoassay and lateral flow format, among others, enabling medical organizations to provide patients with better treatment options for a wide range of medical conditions.
- Sector
- Healthcare
- HQ
- Carlsbad, CA, United States
- Founded
- 2023
- Employees
- 5
- Website
- rose-dx.com/
- Ownership
- Privately Held (backing)
ROSE Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ROSE Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ROSE Diagnostics in its N-PORT filings yet. We sweep new filings monthly.